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CASE PRESENTATION
An active 80-year-old woman presented to her local doctor with a 
lesion in her left popliteal fossa. The patient had no history of 
trauma to the area, no pain from the lesion and, aside from some 
discomfort due to the lesion’s location and tendency to bleed, experi-
enced no other local or systemic symptoms. First noticed by the 
patient in mid December as a hard blood blister, the lesion grew 
rapidly and, when it was excised in early February, it measured 25 mm 
× 23 mm. Initial histopathology described it as a neoplastic infiltrate 
involving dermis and subcutis of uncertain histogenesis. A computed 
tomography scan of her chest, abdomen and pelvis was conducted in 
mid February, which showed no evidence of metastatic disease. Due 
to the uncertainty of the diagnosis, the patient was referred to a ter-
tiary centre for expert opinion. In early March, following specialized 
staining tests, a supplementary pathology report was issued favouring 
the lesion as a malignant small round cell tumour consistent with 
primitive neuroectodermal tumour (PNET). Clinical examination 
by the radiation oncology team in March suggested local recurrence 
that was confirmed with a positron emission tomography scan, focal 
lymphadenopathy and, additionally, two suspicious lung lesions. 
Re-excised in April by the plastics and reconstructive surgical team, 
the visible lesion had regrown to approximately 70 mm in length 
(Figure 1).
Intraoperatively, the exophytic mass was found to have a large 
subcutaneous compartment, tracking between the muscles both 
proximally and distally. Due to the depth of its involvement with the 
neurovascular bundles, clear margins were unable to be obtained. A 
repeat computed tomography scan performed postoperatively showed 
25 new soft tissue nodules throughout the lungs with bulky hilar 
lymphadenopathy. The two lesions observed on the positron emission 
tomography scan one month earlier had grown dramatically, one grow-
ing from 9 mm to 25 mm. No lesions were noted elsewhere.
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A literature review of peripheral primitive neuroectodermal tumours illus-
trated with an index case report describing an 80-year-old woman who 
presented with a mass in the left popliteal fossa is presented. An excision 
biopsy was performed, revealing a possible peripheral primitive neuroecto-
dermal tumour as the primary pathology. Normally confined to the chest 
wall and axial soft tissues of children and young adults, reports of this 
tumour existing in other areas and in the elderly population are scarce.
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Figure 1) Popliteal mass
Figure 2) Hematoxylin and eosin stain of the popliteal tumour. Original 
magnification ×66 (left); ×132 (right)
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Microscopic findings showed a poorly differentiated tumour com-
posed of small round cells with uniform nuclear features, occasional 
prominent nucleoli and indistinct cell borders (Figure 2). Occasional 
conspicuous Homer Wright-like rosettes were identified. The tumour 
was noted to have invaded fat, muscle and vascular tissue. 
Immunohistochemistry was positive for CD99, vimentin, BCL2 and 
CD56. Fluorescence in situ hybridization (FISH) studies were negative 
for the synovial sarcoma rearrangement (18q11.2) and Ewing sarcoma 
(ES) rearrangement (22q12). Due to classical morphology and 
immunohistochemistry staining, PNET was favoured while other dif-
ferential diagnoses, such as Merkel cell tumour, lymphoma, rhabdo-
myocarcoma, synovial sarcoma, melanoma and carcinoma, were 
excluded. Because typical translocation could not be found in the FISH 
study, it was believed this may reflect a subgroup of peripheral PNETs 
(pPNETs), which lack this genetic change. The patient was referred for 
local radiation oncology and systemic chemotherapy.
DISCUSSION
Differential diagnosis of popliteal fossa masses
In adult patients, the most common cause of a popliteal mass is a Baker 
cyst. The differential diagnosis, however, is quite extensive. Classification 
according tissue type can assist with identifying the pathology (Table 1).
pPNETs
pPNETs are an extremely rare cause of a popliteal mass. Believed to 
originate from migrating embryonic cells of the neural crest (3), 
pPNETs are most commonly found in the chest wall and axial soft tis-
sues (4,5), although they have been diagnosed in other areas including 
bone, extra-axial soft tissue and visceral tissues (6-11). Belonging to a 
family of ‘small round-cell tumours’, they are most frequently observed 
in children and young adults, but can occur at any age (12,13). Due to 
their aggressive nature, distant micrometastasis must always be 
assumed to be present and, hence, all patients should receive adjuvant 
chemotherapy for systemic control (13,14). 
pPNETs are commonly classed with ES and Askin’s tumour 
(pPNETs limited to the thoracopulmonary region) as members of the 
Ewing family of tumours (8,12,13,15-17). They have almost identical 
pathological, immunohistochemical and genetic features, with the 
main distinct difference being that tumours demonstrating neural dif-
ferentiation are labelled pPNET while those that are undifferentiated 
are diagnosed as ES (3,12,15,18,19). Due to this subtle distinction 
between ES and pPNET, diagnosis can only be made with immuno-
histochemical, electron microscopy and molecular biological studies 
(19). The phenotypic expression distinction has, however, no clinical 
significance (15).
Epidemiologically, pPNET has a peak incidence in the second 
decade of life, with 80% of presentations <20 years of age (15,16). ES 
and pPNET account for 6% to 10% of primary malignant bone 
tumours following osteosarcoma as the second most common group of 
bone sarcomas in children (15,20). It is slightly more prevalent in 
males and more common in whites and Hispanic populations, while rare 
in African and Asian populations; the reasons for this are currently 
unknown (16,21).
Due to its insidious onset, patients often present with a large 
tumour, and as many as 20% to 25% already have detectable distant 
metastatic disease most commonly to the lung, bone and/or bone mar-
row (13,22-24). Nearly all, however, have micrometastases as indi-
cated by a 10% cure rate with local therapy alone (16). In addition to 
localized symptoms (pain, swelling, bleeding), systemic findings can 
occasionally occur including fever, elevated erythrocyte sedimentation 
rate, anemia and leukocytosis (15).
Radiologically, pPNETs often have a large soft tissue component 
(>5 cm on average) and show moderate enhancement with intra-
venous contrast, combined with nonenhancing necrotic areas (13). 
These necrotic areas tend to displace rather than encase adjacent 
organs. If they do involve adjacent bone, however, they tend to 
exhibit lytic/erosive change (13).
Macroscopically, pPNETs are usually soft, tan-white in colour, 
and frequently contain areas of hemorrhage and necrosis with calci-
fication also noted occasionally (13,15). Microscopically, they typ-
ically consist of sheets of small monomorphic round dark cells with 
small hyperchromatic inconspicuous nuclei and scant cytoplasm 
(25). Extensive necrosis is usually present (16). A common finding 
in pPNET is the presence of Homer Wright rosettes (tumour cells 
arranged in a circle about a central fibrillary space), which is indica-
tive of neural differentiation (7,15,26). 
Because pPNET shows neuroepithelial differentiation, immuno-
histochemistry can be used to test for neurospecific proteins including 
NSE, Leu-7, enolase, synaptophysin, S-100 protein, PGP 9.5, secre-
togranin II, vimentin and keratin (19,27). Additionally, electron 
microscopy can also be used to reveal features of neural differentiation 
(eg, neurosecretory granules, neurofilaments and neurotubules) (28).
Eighty-five percent of tumours diagnosed as either ES or pPNET 
have the translocation t(11;22)(q24;q12) (15,16) (Figure 3). This 
translocation results in the division of two genes known as Friend 
Figure 3) Schematic diagram of t(11;22)(q24;q12), observed in up to 
85% of Ewing sarcoma/peripheral primitive neuroectodermal tumour. 
Adapted from reference 16
TABLE 1
Differential diagnosis of popliteal fossa masses
Tissue type Examples
Skin and subcutaneous tissue Sebaceous cyst, carbuncle, lipomas, abscess, hemangiomas, skin malignancies, sarcomas, cellulitis
Muscle Contusions of gastrocnemius or semimembranosus
Bursae Synovial cysts (Baker), meniscal cysts, popliteal cystic tumours
Vascular Varicocele, thrombophlebitis, arteriovenous malformations/fistulas, aneurysms, vascular tumours, deep vein thrombosis
Lymphatics Enlarged popliteal nodes (secondary to tuberculosus adenopathy, distal infection or metastatic malignancy), lymphangioma 
Nerves Nerve sheath tumours (eg neurilemoma), peripheral nerve tumours (eg, perineuroma, PNET), neurofibroma, ganglion 
Bone, periosteum and cartilage Exostosis arising from epiphyseal cartilage of femur in children, medullary giant cell tumours, fibrosarcomas of the periosteum, 
osteomyelitis, fractures, chondroma
Data adapted from references 1 and 2. PNET Primitive neuroectodermal tumour
PNET – a rare cause of popliteal fossa mass
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leukemia virus integration 1 (FLI-1) gene and ES (EWS) gene. The 
FLI-1 gene on 11q24 is a member of a large family of DNA-binding 
transcription factors that are implicated in the control of cellular pro-
liferation, development and tumorigenesis (14,29). The EWS gene on 
22q12 is believed to be involved in messenger RNA transcription 
(30). These two genes fuse to form a functional EWS-FLI-1 gene, 
which results in abnormal cell proliferation and survival (16). This 
gene rearrangement is detected with FISH studies and is pathognom-
onic of ES/PNET (19). The remaining 15% have variants including 
22q12,21q2 (10%), 7p22, 17q12 and 2q36 (<1%) (19).
Another highly specific test performed to identify a pPNET is 
immunohistochemical staining of an antigen for the MIC2 gene. The 
product of the MIC2 gene − CD99 − is a cell surface glycoprotein 
involved in cell adhesion. It is highly sensitive for pPNET; however, it 
has been known to occur in other tumours, such as 30% of carcinoid 
tumours, thus lacks specificity (26,31-33). 
Treatment for pPNET consists primarily of systemic intensive 
multi-agent chemotherapy with surgery and/or radiotherapy for local 
control, inoperable tumours or lesions unresponsive to chemotherapy 
(16,22), although the relative efficacies of these local treatments 
remain controversial (18). Multi-agent chemotherapy is recom-
mended due to the tumour’s strong propensity for metastasis (18). In 
one study, chemotherapy has been shown to improve five-year survival 
from 5% to 15% to 75%, with up to 50% having long-term cures (15). 
In 2003, Shamberger et al (34) suggested that the preferred treatment 
sequence is after initial biopsy for adjuvant chemotherapy with 
delayed resection after four courses of treatment. This is believed to 
avoid the need for radiotherapy (and associated complications). 
Although study numbers are relatively small, five-year survival 
rates are approximately 40% to 60%, with patients with metastatic 
disease at diagnosis having a much poorer outcome well below 30% 
five-year survival (18,25,35) (Table 2). Consistently adverse prognos-
tic factors include larger tumour size (>5 cm to 8 cm), metastasis at 
time of diagnosis and bone metastasis (9,18,25,36-38). 
Several studies have reported a poorer prognosis with older 
patients (18,39); however, this finding is not consistent across all stud-
ies (40). A study by Verill et al (37) involving 59 patients showed 
adults had a similar prognosis, with a 38% five-year survival rate (52% 
if localized). A reason proposed by Baldini et al (18) for more favour-
able outcomes in younger patients is that they have more bone marrow 
reserve to tolerate the long chemotherapy regimens that have been 
used. Five-year local recurrence rates are approximately 15% 
(18,35,41).
The incidence of pPNET is likely to be under-reported in the lit-
erature. Recent cytogenetic and immunohistochemical advances have 
enabled these tumours to be distinguished from other small, poorly 
differentiated round cell tumours such as neuroblastoma, rhabdo-
myosarcoma and lymphoma (42). Research investigating targeted 
molecular therapies is underway (43).
CONCLUSION
The present case demonstrates a rare pathology not only for this age 
group but also for a popliteal fossa mass. It is always important to con-
sider the rare and serious causes when diagnosing a lesion.
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TABLE 2
Five-year local recurrence rates
Author (reference) Patients, n
Five-year survival rate, %
Overall If metastasized at diagnosis If localized disease only at diagnosis
Baldini et al (18) 37 37 0 (n=11) 49 (n=24)
Kolb et al (22) 68 17.8 (four-year survival) (n=24) 89 (four-year survival) (n=44)
Smorenburg et al (25) 27 58 60 (n=10) 52 (n=17)
Martin and Brennan (35) 59 60 33 60
Fizazi et al (21) 182 41 9 (n=53) 54 (n=129)
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